Blog
Published August 2, 2021
Executive Summary:
A CMS regulation from the Trump Administration requiring hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021 but is still widely ignored by hospitals
A lack of enforcement coupled with minor penalties decreases the efficacy of the requirement, resulting in low incentive for hospitals to comply with the rule
The data posted by compliant hospitals shows large variation in pricing for…
Read Now
Briefs
The elimination of third-party cookies is not a new concept. Safari and FireFox eliminated them a few years back. However, now the largest used browser (Chrome) is joining FireFox and Safari, announcing the imminent removal of third-party cookies in 2022. Organizations are attempting to navigate the impact and identify alternatives. Driven by increased user privacy, Google’s decision will require fundamental changes across media and advertising platforms.
The departure of third-party cookies will change the way pharmaceutical companies, in fact all…
Read Now
White Papers
Despite the challenges the COVID-19 pandemic created, 2020 was an exceptional year for the biopharma industry. The race to develop effective treatments and vaccines for COVID elevated the public’s perception of biotechnology, and, for many, the industry provided a source of hope during the pandemic. As early-stage venture capitalist Bruce Booth observed in his review of 2020, investors’ enthusiasm sent biotech indexes to all-time highs, boosted the performance of IPOs and accelerated venture capital funding. The NASDAQ Biotech Index finished…
Read Now
White Papers
In this article, we aim to explain how monoclonal antibodies can help in the fight against the COVID-19 pandemic. While there are still unknowns about these drugs – such as their real-life efficacy and long-term effects, amongst others –antibodies nonetheless have the potential to effectively target several stages of the disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the overburdened health…
Read Now
Webinars
Available On Demand
Let’s face it, data management in the life science industry is tough regardless of the size of the company or the lifecycle of its products. For pre-commercial and emerging companies, the challenges with enabling the commercial data environment may seem insurmountable – from identifying data needs and system and process requirements to justifying resources to senior level executives and the Board to hiring the right talent and skill sets…Trinity Life Sciences has extensive experience helping pre-commercial and emerging companies establish…
Watch Now
Briefs
As the year began, we couldn’t have foreseen the unprecedented impact the COVID-19 pandemic would have on US and Global enterprises. By mid-March, we were in lock-down, and priorities for Commercial and Medical Affairs organizations in the life sciences industry shifted. Leaders were working feverishly to enable virtual and digital channels to engage with customers as well as internal teams. Companies reached out to TGaS Advisors for our guidance in navigating this uncharted territory, and we stepped up to proactively…
Read Now
Webinars
Available On Demand
Watch our webinar recording of Curt Staab, Sr. Vice President of Emerging Life Sciences Network as he draws from the latest landscape findings about how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the pandemic.
We explore how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the COVID-19 pandemic.
By submitting this form, creating an account, and/or using our website (or using…
Watch Now
Webinars
Available On Demand
A Biopharma Industry Perspective on the Current and Future State of Incentive Compensation
Trinity Life Sciences shares highlights from our latest TGaS Landscape report entitled, “Tenth Annual Incentive Compensation Landscape.” This highly anticipated report is based on interviews of 38 biopharmaceutical incentive compensation (IC) leaders who shared their experiences on IC planning.
The Tenth Annual edition is perhaps more critical than ever before as companies adapt IC approaches and plan amid COVID-19 challenges. From implementing COVID-specific Management by Objective (MBO)…
Watch Now
Briefs
Trinity has heard numerous organizations express frustration with their data management provider. Common challenges include quality issues, timeliness and lack of flexibility. Switching to another provider isn’t as hard as you think. In this advisory brief, we outline the top five things to keep in mind if you are considering a switch.
Please complete the form to download a copy of our Advisory Brief: Frustrated with Your Current Data Management Provider?
By submitting this form, creating an account, and/or using…
Read Now
White Papers
What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-downs began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking.
In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful drug launch (and avoid the pitfalls) in the age of COVID-19.
By submitting this form, creating an account, and/or using our website (or…
Read Now
